Griseofulvin [Ultra Microsize] interactions
Checked as Griseofulvin in this data source.
Full monograph for Griseofulvin [Ultra Microsize]Check it against another medicine
Medicines
183 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Cyproterone Acetate + Ethinyl Estradiol | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance… | 48 sources — open the full entry |
| Desogestrel | Major | Metabolism | Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones.The proposed mechanism is accelerated clearance of the… | 13 sources — open the full entry |
| Dienogest | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance…2 documented mechanisms | 61 sources — open the full entry |
| Dienogest + Estradiol Valerate | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance…3 documented mechanisms | 111 sources — open the full entry |
| Drospirenone | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance… | 48 sources — open the full entry |
| Drospirenone + Estetrol | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance… | 48 sources — open the full entry |
| Drospirenone + Estradiol | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance…2 documented mechanisms | 98 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol0.02 mg0.03 mg | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance…2 documented mechanisms | 48 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol + Levomefolate | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance…2 documented mechanisms | 48 sources — open the full entry |
| Ethinyl Estradiol + Desogestrel0.02 mg0.03 mg | Major | Metabolism | Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones.The proposed mechanism is accelerated clearance of the…2 documented mechanisms | 61 sources — open the full entry |
| Ethinyl Estradiol + Gestodene | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance… | 48 sources — open the full entry |
| Ethinyl Estradiol + Levonorgestrel + Ferrous Fumarate | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance…2 documented mechanisms | 48 sources — open the full entry |
| Ethinyl Estradiol + Lynestrenol0.0375 mg0.05 mg | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance… | 48 sources — open the full entry |
| Levonorgestrel [For emergency contraception] | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance… | 48 sources — open the full entry |
| Medroxyprogesterone AcetateInjectionTablet | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance… | 48 sources — open the full entry |
| Norethisterone Acetate | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance… | 48 sources — open the full entry |
| Norgestrel + Ethinyl Estradiol + Ferrous Fumarate | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance…2 documented mechanisms | 48 sources — open the full entry |
| Norgestrel [For breastfeeding mother] | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance… | 48 sources — open the full entry |
| Ranolazine | Major | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. | 12 sources — open the full entry |
| Relugolix + Estradiol + Norethindrone | Major | Metabolism · Others | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance…3 documented mechanisms | 99 sources — open the full entry |
| Abemaciclib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of abemaciclib and its pharmacologically active metabolites, all of which… | 2 sources — open the full entry |
| Acalabrutinib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme. | 2 sources — open the full entry |
| Alpelisib | Moderate | Metabolism | Coadministration of alpelisib with inducers of CYP450 3A4 may reduce the plasma concentrations of alpelisib. The proposed mechanism, based on in vitro data, is… | 2 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of atorvastatin and its active metabolites, all of which are substrates of… | 12 sources — open the full entry |
| Apixaban | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of apixaban, which is a substrate of both the… | 11 sources — open the full entry |
| Apremilast | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of apremilast, which is primarily metabolized by the isoenzyme in vitro. | 1 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme. | 12 sources — open the full entry |
| Aripiprazole | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aripiprazole, which is partially metabolized by the isoenzyme. | 10 sources — open the full entry |
| Armodafinil | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are… | 14 sources — open the full entry |
| Artemether + Lumefantrine | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by…2 documented mechanisms | 19 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of atorvastatin and its active metabolites, all of which are substrates of… | 12 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of atorvastatin and its active metabolites, all of which are substrates of… | 12 sources — open the full entry |
| Avanafil | Moderate | Metabolism | Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme. | 10 sources — open the full entry |
| Axitinib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme. | 3 sources — open the full entry |
| Brexpiprazole | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of brexpiprazole. In vitro and in vivo data indicate that brexpiprazole is… | 3 sources — open the full entry |
| Brigatinib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of brigatinib, which is partially metabolized by the isoenzyme. | 4 sources — open the full entry |
| Bromocriptine Mesylate | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bromocriptine. | 4 sources — open the full entry |
| BudesonideInhalerNebuliser SuspensionTablet | Moderate | Absorption · Metabolism | Concomitant use of orally and rectally administered formulations of budesonide with inducers of CYP450 3A4 may decrease budesonide systemic as well as local… | 2 sources — open the full entry |
| Budesonide + Formoterol Fumarate | Moderate | Absorption · Metabolism | Concomitant use of orally and rectally administered formulations of budesonide with inducers of CYP450 3A4 may decrease budesonide systemic as well as local… | 2 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Absorption · Metabolism | Concomitant use of orally and rectally administered formulations of budesonide with inducers of CYP450 3A4 may decrease budesonide systemic as well as local… | 2 sources — open the full entry |
| Cabazitaxel | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cabazitaxel, which is primarily metabolized by the… | 6 sources — open the full entry |
| Cabozantinib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of cabozantinib, which is a substrate of the isoenzyme. | 13 sources — open the full entry |
| Capmatinib Hydrochloride | Moderate | Metabolism | Coadministration with CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed mechanism involves… | 11 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of carbamazepine, which is primarily metabolized… | 11 sources — open the full entry |
| Cariprazine | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 is expected to alter the pharmacokinetics of cariprazine and its major active metabolites. Cariprazine is… | 4 sources — open the full entry |
| Caspofungin Acetate | Moderate | Metabolism | Coadministration with inducers or mixed inducer/inhibitors of certain metabolic pathways may produce clinically meaningful reductions in the plasma… | 2 sources — open the full entry |
| Ceritinib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. | 2 sources — open the full entry |
| Conjugated EstrogenCreamTablet | Moderate | Metabolism | RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in… | 50 sources — open the full entry |
| Conjugated Estrogen + Bazedoxifene | Moderate | Metabolism | RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in… | 50 sources — open the full entry |
| Crizotinib | Moderate | Metabolism | Coadministration with CYP450 3A4 inducers may decrease plasma concentrations and pharmacologic effects of crizotinib, which is primarily metabolized by the… | 14 sources — open the full entry |
Food & lifestyle
alcohol
ModerateSynergy
Isolated case reports have suggested that the ingestion of alcohol during griseofulvin therapy may rarely cause disulfiram-like reactions, flushing, tachycardia, or increased effects of alcohol.
What to do: Patients should be advised of the possibility of increased adverse effects or a disulfiram-like reaction.
3 sources
- "Product Information. Grifulvin V (griseofulvin)." Ortho McNeil Pharmaceutical
- "Product Information. Fulvicin P/G (griseofulvin)." Schering Corporation (2002):
- Cerner Multum, Inc. "Australian Product Information." O 0
Conditions
Conditions in which Griseofulvin [Ultra Microsize] needs care, as documented in this source.
Liver Diseases
MajorThe use of griseofulvin is contraindicated in patients with hepatocellular failure, as animal data has shown that this drug may cause hepatocellular necrosis. The use of griseofulvin has not been adequately studied in patients with liver disease, although it is known that griseofulvin is primarily metabolized by the liver. Therapy with griseofulvin should be administered very cautiously in patients with liver impairment, and the dosing adjusted or discontinued according to clinical response.
1 source
- "Product Information. Fulvicin P/G (griseofulvin)." Schering Corporation (2002):
Porphyrias
MajorThe use of griseofulvin is contraindicated in patients with porphyria. Griseofulvin has been shown to cause disturbances in porphyrin metabolism in laboratory animals.
1 source
- "Product Information. Fulvicin P/G (griseofulvin)." Schering Corporation (2002):
Lupus Erythematosus, Systemic
ModerateThe use of griseofulvin has been associated with the development of lupus erythematosus and lupus-like syndromes, as well as exacerbation of the disease. Griseofulvin therapy should be withdrawn in patients experiencing worsening of preexisting lupus until another cause can be identified.
4 sources
- Madhok R, Zoma A, Capell H "Fatal exacerbation of systemic lupus erythematosus after treatment with griseofulvin." Br Med J (Clin Res Ed) 291 (1985): 249-50
- Miyagawa S, Okuchi T, Shiomi Y, Sakamoto K "Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin." J Am Acad Dermatol 21 (1989): 343-6
- Miyagawa S, Sakamoto K "Adverse reaction to griseofulvin in patients with circulating anti-ssa/ro and ssb/la autoantibodies." Am J Med 87 (1989): 99-102
- "Product Information. Fulvicin P/G (griseofulvin)." Schering Corporation (2002):